The Lancet infectious diseases
The most recent articles from:
Lancet Infect Dis
-
Comment Letter
Health-care-associated bloodstream infections in France.
-
Randomized Controlled Trial Multicenter Study
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
Rates of sustained virological response (SVR) to peginterferon-ribavirin are low in patients with hepatitis C virus (HCV) genotype 1 and HIV. We aimed to assess efficacy and safety of triple therapy with boceprevir plus pegylated interferon alfa-2b (peginterferon) and ribavirin, which increases rates of SVR in patients with HCV alone. ⋯ Merck.
-
Middle East coronavirus is causing alarm among researchers and international health officials. Neil Bennet looks at the unfolding situation.